Novo Nordisk A/S
NVONYSE
USReal-Time Price
USReal-Time Price$38.42USD
-0.41 (-1.06%)Today
$38.81+0.39 (+1.02%)Pre-Market7:37 AM ET
BTI Score
Near Future
50
Long Term
62
BTI Fair Market Cap
$301.44B
-43.45% vs fair
Healthcare & Pharma
Strong Buy
Novo Nordisk A/S (NVO) Stock Analysis
BTI's proprietary analysis of Novo Nordisk A/S (NVO): overall score, long- and short-term outlook, risk rating and fair-value verdict based on fundamentals, valuation and momentum.
Major-Firm Consensus
Hold
Filtered to 36 major global investment banks
Buy
11
Hold
22
Sell
3
Price Target Consensus
High
$62.03
Consensus
$45.80
Low
$39.90
Current
$38.42
Upside: +19.2%
Target Trend
Last Month— (0)
Last Quarter— (0)
Last Year— (0)
Ratings History — Major Investment Banks
| Firm | Rating | Action | Previous | Price Target | Upside | Date |
|---|---|---|---|---|---|---|
| Berenberg Bank | Hold | Maintains | — | $47.00 | +22.3% | Oct 14, 2026 |
| BMO Capital | Hold | Maintains | — | — | — | Oct 12, 2026 |
| TD Cowen | Hold | Maintains | — | $42.00 | +9.3% | Sep 23, 2026 |
| Jefferies | Hold | Maintains | — | $42.00 | +9.3% | Sep 22, 2026 |
| Morgan Stanley | Sell | Downgrades | — | $40.00 | +4.1% | Sep 11, 2026 |
| Goldman Sachs | Hold | Maintains | — | — | — | Aug 7, 2026 |
| Argus Research | Hold | Maintains | — | — | — | Aug 7, 2026 |
Annual Analyst Estimates
| Fiscal Year | Revenue Avg | Revenue Range | EPS Avg | EPS Range | Analysts |
|---|---|---|---|---|---|
| FY 2026 | $302.07B | — – — | $21.83 | — – — | — |
| FY 2027 | $305.94B | — – — | $22.13 | — – — | — |
Want deeper AI-powered analysis?
Get BTI AI's full investment thesis, valuation models, and risk assessment for NVO.